National Comprehensive Cancer Network 2020 guidelines: BCR-ABL1 transcript monitoring policy after tyrosine kinase inhibitor removal
| NCCN 2020 . |
|---|
| Monthly during the first year |
| Every 2 mo during the second year |
| Every 3 mo after the second year |
| After TKI reintroduction in case of molecular relapse: monthly until MMR recovery, then every 3 mo |
| NCCN 2020 . |
|---|
| Monthly during the first year |
| Every 2 mo during the second year |
| Every 3 mo after the second year |
| After TKI reintroduction in case of molecular relapse: monthly until MMR recovery, then every 3 mo |
MMR, major molecular response; NCCN, National Comprehensive Cancer Network; TKI, tyrosine kinase inhibitor.